Drug Profile

QEV 817

Alternative Names: QEV-817

Latest Information Update: 07 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Quivive Pharma
Class Analgesics; Antitussives; Morpholines; Opioid analgesics; Opioid peptides; Pyrrolidinones; Respiratory stimulants; Small molecules
Mechanism of Action Central nervous system stimulants; Chemoreceptor cell stimulants; Opioid receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

05 Sep 2024 Quivive Pharma plans a phase I trial (In volunteers) in USA (PO, Suspension) in September 2024 (NCT06585163)
03 Jul 2018 Quivive has patent protection for QEV 817 in USA (Quivive Pharma website, September 2024)
04 May 2017 Preclinical trials in Acute pain in USA (PO) (Quivive Pharma website, September 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com